Sage Therapeutics, Inc. (SAGE)
| Market Cap | 2.44B |
| Revenue (ttm) | 1.11B |
| Net Income (ttm) | 666.15M |
| Shares Out | 58.58M |
| EPS (ttm) | 11.84 |
| PE Ratio | 3.50 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 321,589 |
| Open | 41.15 |
| Previous Close | 41.42 |
| Day's Range | 40.75 - 41.85 |
| 52-Week Range | 39.77 - 98.39 |
| Beta | 1.86 |
| Analysts | Buy |
| Price Target | 79.32 (+91.5%) |
| Est. Earnings Date | Nov 2, 2021 |
About SAGE
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and generalized anxiety disorders; and SAGE-324, a compound that is in Phase II clinical ...
Financial Performance
Financial StatementsAnalyst Forecast
According to 21 analysts, the average rating for SAGE stock is "Buy." The 12-month stock price forecast is 79.32, which is an increase of 91.46% from the latest price.
News
Sage Therapeutics to Report Third Quarter 2021 Financial Results on Tuesday, November 2, 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with de...
Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced their plan to submit a New Drug Application (NDA) to the U.S. Food and Drug Admin...
Top 3 undervalued US biotech stocks to buy
With the US Q3 earnings season just getting started, there are a few biotech stocks that present an exciting opportunity for value investors. Some of these stocks look significantly undervalued after a ...
Sage Therapeutics and Biogen Announce Consistent Clinically Meaningful Data for Zuranolone Across the LANDSCAPE and N...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced new data from the LANDSCAPE and NEST clinical development programs evaluating the...
Sage Therapeutics Launches SageCitizen Social Impact Initiative
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilita...
Sage Therapeutics Appoints Chris Benecchi as Chief Commercial Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilita...
Why Sage Therapeutics Shares Are Trading Higher Today
Sage Therapeutics (NASDAQ:SAGE) shares are trading higher after the company announced it received Fast Track Designation for SAGE-718 or the treatment of Huntington's disease. Sage Therapeutics is curre...
Sage Therapeutics Receives Fast Track Designation for SAGE-718 for the Treatment of Huntington's Disease
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with deb...
Sage Therapeutics to Present at the Morgan Stanley Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with de...
These 3 Stocks Appear Underestimated by the Market
When searching for value opportunities, investors could be interested in the following stocks, since their prices are trading at a discount to the intrinsic value calculated by GuruFocus' earnings-based...
Sage Therapeutics to Present at Upcoming August Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with de...
Sage Therapeutics Drops Two Zuranolone Depression Trials Deemed Unnecessary For Approval
Tucked in the Q2 earnings release, Sage Therapeutics Inc (NASDAQ: SAGE) has terminated two long-suspended Phase 3 zuranolone trials in major depressive disorder (MDD). What Happened: After talks with th...
Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Lags Revenue Estimates
Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of -8.28% and -19.34%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Sage Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Today, Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people ...
Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Sage Therapeutics, Inc. (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sage Therapeutics to Report Second Quarter 2021 Financial Results on Tuesday, August 3, 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with de...
Late-Stage Clinical Study Readouts Biotech Investors Should Watch
Several drugmakers have important clinical trial updates on the way.
Sage Therapeutics to Participate in Cowen's Psychedelics & Novel Mechanisms in Neuropsychiatry Summit
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with de...
These are the stocks seeing the most insider buying this week
Brian Sullivan brings you the top five stocks seeing the most insider buying action this week, on Worldwide Exchange with data from Insiderscore.com.
Sage Therapeutics to Participate in SVB Leerink's 3rd Annual CNS Forum
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with de...
What Happened to Sage Therapeutics Stock?
Sage has been struggling for some time to bring its flagship antidepressant to the market.
Here's Why Sage Therapeutics Tanked This Week
The neuroscience-focused biotech company didn't give investors the result they wanted.
4 Undervalued Biotech Stocks That Belong On Every Investor's Buy List
Searching for undervalued biotech stocks? Here are 4 biotech stocks to buy for a mix of value and growth in any portfolio.
Sage Stock Declines on Late-Stage Depression Study Data
Sage is developing zuranolone as a potential treatment for major depression disorder in late-stage studies.